Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, Japan.
Breast Cancer. 2011 Jan;18(1):64-7. doi: 10.1007/s12282-010-0198-5. Epub 2010 Mar 31.
A suggestive case of metastatic disease from breast cancer is reported. The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib. After re-induction of trastuzumab in combination with activated natural killer (NK) cell injection therapy, tumor markers decreased, and finally a synergistic effect of taxane and capecitabine led to treatment response. This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease.
报告了一例转移性乳腺癌的疑似病例。该 HER-2 阳性肿瘤对包括抗 HER-2 治疗、曲妥珠单抗和拉帕替尼在内的多种药物均耐药。在重新诱导曲妥珠单抗联合激活自然杀伤 (NK) 细胞注射治疗后,肿瘤标志物下降,最终紫杉醇和卡培他滨联合发挥协同作用,导致治疗反应。该病例提示,包括免疫治疗在内的多学科治疗可能是治疗耐药疾病的突破。